Association of Treatment Dose Anticoagulation With In-Hospital Survival Among Hospitalized Patients With COVID-19

Ishan Paranjpe; Valentin Fuster; Anuradha Lala; Adam J. Russak; Benjamin S. Glicksberg; Matthew A. Levin; Alexander W. Charney; Jagat Narula; Zahi A. Fayad; Emilia Bagiella; Shan Zhao; Girish N. Nadkarni

doi:10.1016/j.jacc.2020.05.001

Association of Treatment Dose Anticoagulation With In-Hospital Survival Among Hospitalized Patients With COVID-19

Ishan Paranjpe, Valentin Fuster, Anuradha Lala, Adam J. Russak, Benjamin S. Glicksberg, Matthew A. Levin, Alexander W. Charney, Jagat Narula, Zahi A. Fayad, Emilia Bagiella, Shan Zhao, Girish N. Nadkarni

Research output: Contribution to journal › Letter › peer-review

628 Scopus citations

Original language	English
Pages (from-to)	122-124
Number of pages	3
Journal	Journal of the American College of Cardiology
Volume	76
Issue number	1
DOIs	https://doi.org/10.1016/j.jacc.2020.05.001
State	Published - 7 Jul 2020

Access to Document

10.1016/j.jacc.2020.05.001

Cite this

Paranjpe, I., Fuster, V., Lala, A., Russak, A. J., Glicksberg, B. S., Levin, M. A., Charney, A. W., Narula, J., Fayad, Z. A., Bagiella, E., Zhao, S., & Nadkarni, G. N. (2020). Association of Treatment Dose Anticoagulation With In-Hospital Survival Among Hospitalized Patients With COVID-19. Journal of the American College of Cardiology, 76(1), 122-124. https://doi.org/10.1016/j.jacc.2020.05.001

@article{0ecf8e71b7984be1a5dc9feff8d5180a,

title = "Association of Treatment Dose Anticoagulation With In-Hospital Survival Among Hospitalized Patients With COVID-19",

author = "Ishan Paranjpe and Valentin Fuster and Anuradha Lala and Russak, {Adam J.} and Glicksberg, {Benjamin S.} and Levin, {Matthew A.} and Charney, {Alexander W.} and Jagat Narula and Fayad, {Zahi A.} and Emilia Bagiella and Shan Zhao and Nadkarni, {Girish N.}",

note = "Funding Information: Please note: This work was supported by U54 TR001433-05, National Center for Advancing Translational Sciences, National Institutes of Health. Dr. Fayad has received consulting fees from Alexion and GlaxoSmithKline; has received research funding from Daiichi-Sankyo, Amgen, Bristol-Myers Squibb, and Siemens Healthineers; and has received financial compensation as a board member and advisor to and owns equity as a co-founder of Trained Therapeutix Discovery. Dr. Nadkarni has received financial compensation as a consultant and Advisory Board member for and owns equity in RenalytixAI; is a scientific co-founder of RenalytixAI and Pensieve Health; has received operational funding from Goldfinch Bio; and has received consulting fees from BioVie Inc., AstraZeneca, Reata, and GLG consulting in the past 3 years. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose. P.K. Shah, MD, served as Guest Editor-in-Chief and Guest Associate Editor for this paper. Funding Information: Please note: This work was supported by U54 TR001433-05, National Center for Advancing Translational Sciences, National Institutes of Health. Dr. Fayad has received consulting fees from Alexion and GlaxoSmithKline; has received research funding from Daiichi-Sankyo, Amgen, Bristol-Myers Squibb, and Siemens Healthineers; and has received financial compensation as a board member and advisor to and owns equity as a co-founder of Trained Therapeutix Discovery. Dr. Nadkarni has received financial compensation as a consultant and Advisory Board member for and owns equity in RenalytixAI; is a scientific co-founder of RenalytixAI and Pensieve Health; has received operational funding from Goldfinch Bio; and has received consulting fees from BioVie Inc., AstraZeneca, Reata, and GLG consulting in the past 3 years. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose. P.K. Shah, MD, served as Guest Editor-in-Chief and Guest Associate Editor for this paper.",

year = "2020",

month = jul,

day = "7",

doi = "10.1016/j.jacc.2020.05.001",

language = "English",

volume = "76",

pages = "122--124",

journal = "Journal of the American College of Cardiology",

issn = "0735-1097",

publisher = "Elsevier USA",

number = "1",

}

Paranjpe, I, Fuster, V, Lala, A, Russak, AJ, Glicksberg, BS , Levin, MA , Charney, AW, Narula, J, Fayad, ZA , Bagiella, E, Zhao, S & Nadkarni, GN 2020, 'Association of Treatment Dose Anticoagulation With In-Hospital Survival Among Hospitalized Patients With COVID-19', Journal of the American College of Cardiology, vol. 76, no. 1, pp. 122-124. https://doi.org/10.1016/j.jacc.2020.05.001

TY - JOUR

T1 - Association of Treatment Dose Anticoagulation With In-Hospital Survival Among Hospitalized Patients With COVID-19

AU - Paranjpe, Ishan

AU - Fuster, Valentin

AU - Lala, Anuradha

AU - Russak, Adam J.

AU - Glicksberg, Benjamin S.

AU - Levin, Matthew A.

AU - Charney, Alexander W.

AU - Narula, Jagat

AU - Fayad, Zahi A.

AU - Bagiella, Emilia

AU - Zhao, Shan

AU - Nadkarni, Girish N.

N1 - Funding Information: Please note: This work was supported by U54 TR001433-05, National Center for Advancing Translational Sciences, National Institutes of Health. Dr. Fayad has received consulting fees from Alexion and GlaxoSmithKline; has received research funding from Daiichi-Sankyo, Amgen, Bristol-Myers Squibb, and Siemens Healthineers; and has received financial compensation as a board member and advisor to and owns equity as a co-founder of Trained Therapeutix Discovery. Dr. Nadkarni has received financial compensation as a consultant and Advisory Board member for and owns equity in RenalytixAI; is a scientific co-founder of RenalytixAI and Pensieve Health; has received operational funding from Goldfinch Bio; and has received consulting fees from BioVie Inc., AstraZeneca, Reata, and GLG consulting in the past 3 years. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose. P.K. Shah, MD, served as Guest Editor-in-Chief and Guest Associate Editor for this paper. Funding Information: Please note: This work was supported by U54 TR001433-05, National Center for Advancing Translational Sciences, National Institutes of Health. Dr. Fayad has received consulting fees from Alexion and GlaxoSmithKline; has received research funding from Daiichi-Sankyo, Amgen, Bristol-Myers Squibb, and Siemens Healthineers; and has received financial compensation as a board member and advisor to and owns equity as a co-founder of Trained Therapeutix Discovery. Dr. Nadkarni has received financial compensation as a consultant and Advisory Board member for and owns equity in RenalytixAI; is a scientific co-founder of RenalytixAI and Pensieve Health; has received operational funding from Goldfinch Bio; and has received consulting fees from BioVie Inc., AstraZeneca, Reata, and GLG consulting in the past 3 years. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose. P.K. Shah, MD, served as Guest Editor-in-Chief and Guest Associate Editor for this paper.

PY - 2020/7/7

Y1 - 2020/7/7

UR - http://www.scopus.com/inward/record.url?scp=85084617029&partnerID=8YFLogxK

U2 - 10.1016/j.jacc.2020.05.001

DO - 10.1016/j.jacc.2020.05.001

M3 - Letter

C2 - 32387623

AN - SCOPUS:85084617029

SN - 0735-1097

VL - 76

SP - 122

EP - 124

JO - Journal of the American College of Cardiology

JF - Journal of the American College of Cardiology

IS - 1

ER -